Chaperones as a Novel Target Against Amyloids in Parkinson¿s Disease - Chaari, Ali
26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Protein misfolding and amyloid formation is an underlying pathological hallmark in a number of prevalent diseases of protein aggregation, including Parkinson's disease (PD), Alzheimer's disease and Type 2 diabetes. Most importantly, the severity of these diseases appears to correlate with the degree of the deposition of amyloid aggregates. The misfolding of -synuclein, a protein involved in PD, followed by its aggregation has been shown to be highly cytotoxic and to play a key role in the death of neurons. Thus, the modulation of the aggregation process, promoting the proper folding of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Protein misfolding and amyloid formation is an underlying pathological hallmark in a number of prevalent diseases of protein aggregation, including Parkinson's disease (PD), Alzheimer's disease and Type 2 diabetes. Most importantly, the severity of these diseases appears to correlate with the degree of the deposition of amyloid aggregates. The misfolding of -synuclein, a protein involved in PD, followed by its aggregation has been shown to be highly cytotoxic and to play a key role in the death of neurons. Thus, the modulation of the aggregation process, promoting the proper folding of -synuclein, may be considered as an attractive avenue for a therapeutic intervention. Indeed, molecular chaperones have been shown to assist in the maintenance of a functional proteome in vivo and to prevent protein misfolding, aggregation and amyloid formation.
Autorenporträt
Dr. Ali CHAARI est né le 24 mars 1982 à Sfax/Tunisie. Titulaire d¿un diplôme d¿ingénieur en Biotechnologie auprès de l¿Ecole Nationale des Ingénieurs de Sfax (ENIS) et d¿un doctorat en Biochimie et Biologie Moléculaire de l¿Université de Versailles Saint Quentin en Yvelines. Actuellement il est chercheur à Weill Cornell Medical College au Qatar.